Kadmon (KDMN) to Offer Common Stock

Kadmon Holdings, Inc. (NYSE: KDMN) ("Kadmon") today announced its intention to offer and sell shares of its common stock in a public offering pursuant to its existing shelf registration statement. Kadmon also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Jefferies LLC and Cantor Fitzgerald & Co. are acting as joint book-running managers for the offering. H.C. Wainwright & Co., LLC and Oppenheimer & Co. Inc. are acting as co-lead managers for the offering.

Kadmon intends to use the net proceeds from the offering for the clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates, and other general corporate purposes.

You May Also Be Interested In

• IDEAYA Biosciences closes $345 million public offering
• Genco board commits to limit rights agreement extensions to 12 months
• Humacyte prices $50 million stock offering at $1.05 per share